1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

22 Feb 2022
Admin
News Article

Sandoz launches generic Revlimid in 19 countries in Europe

Since Bristol Myers Squibb acquired Celgene and its megablockbuster Revlimid, it has girded for the day the multiple myeloma superstar would face generics. In many European countries, that day is here. On Friday, Novartis' Sandoz revealed that it has launched its generic version of the medicine in 19 countries in Europe. German generics maker Stada Arzneimittel also has launched its Revlimid generic in Europe, according to reports. Lenalidomide will provide cost savings for patients, Sandoz said, expanding treatment options for those with multiple myeloma, previously treated follicular lymphoma or relapsed or refractory mantel cell lymphoma patients. Sandoz, the global generics division of Novartis, is the largest generics producer in Europe. The division of the Swiss pharma giant accounted for $9.8 billion in worldwide sales last year. Last September, Sandoz launched its generic lenalidomide in Canada. Meanwhile, the first Revlimid generics are scheduled to reach the huge United States market next month. The drug generated $12.8 billion for BMS last year, the company recently reported. With the flood of incoming competition, BMS expects sales of Revlimid to drop to between $9.5 billion and $10 billion this year. Since Revlimid was originally approved in 2006, Celgene worked hard to stave off competition through court battles and settlements. In certain smaller European markets, Alvogen managed to launch its Revlimid generic back in 2019.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!